Stéphanie Deudon

1.1k total citations · 1 hit paper
10 papers, 786 citations indexed

About

Stéphanie Deudon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Stéphanie Deudon has authored 10 papers receiving a total of 786 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Stéphanie Deudon's work include Lung Cancer Treatments and Mutations (5 papers), Fibroblast Growth Factor Research (4 papers) and Advanced Breast Cancer Therapies (3 papers). Stéphanie Deudon is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Fibroblast Growth Factor Research (4 papers) and Advanced Breast Cancer Therapies (3 papers). Stéphanie Deudon collaborates with scholars based in Switzerland, United States and Spain. Stéphanie Deudon's co-authors include Geoffrey Liu, Alessandra Bearz, Enriqueta Felip, Alice T. Shaw, Mario Campone, Tony Mok, Silvia Novello, Cesare Gridelli, Giorgio V. Scagliotti and Katsuyuki Kiura and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Stéphanie Deudon

10 papers receiving 774 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 412 citations Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology profile →

Peers

Stéphanie Deudon

PRM

ONCOL

PFM

Takashi Nakaoku Japan

Alessandra Capodanno Italy

Edna Chow‐Maneval United States

Azusa Tanimoto Japan

Tahsin M. Khan United States

Huamao Mark Lin United States

Renee Iacona United States

Lyudmila Bazhenova United States

Vincent O’Neill United States

Liwen Xiong China

Takashi Nakaoku Japan

Stéphanie Deudon

384 ×0.8

PRM

302 ×0.6

ONCOL

247 ×0.7

191 ×1.1

49 ×0.9

PFM

Citations per year, relative to Stéphanie Deudon Stéphanie Deudon (= 1×) peers Takashi Nakaoku

Countries citing papers authored by Stéphanie Deudon

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Deudon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Deudon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Deudon more than expected).

Fields of papers citing papers by Stéphanie Deudon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Deudon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Deudon. The network helps show where Stéphanie Deudon may publish in the future.

Co-authorship network of co-authors of Stéphanie Deudon

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Deudon. A scholar is included among the top collaborators of Stéphanie Deudon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Deudon. Stéphanie Deudon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Johnson, Bruce E., Tae Min Kim, T. Jeroen N. Hiltermann, et al.. (2020). Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC. Cancer Research. 80(16_Supplement). CT214–CT214. 2 indexed citations

Greystoke, Alastair, et al.. (2019). P2.01-17 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts. Journal of Thoracic Oncology. 14(10). S645–S645. 2 indexed citations

Tan, Daniel Shao-Weng, Benjamin Solomon, Wan Ling Tan, et al.. (2019). CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC. Annals of Oncology. 30. ix179–ix179. 5 indexed citations

Musolino, Antonino, Mario Campone, Patrick Neven, et al.. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Research. 19(1). 18–18. 87 indexed citations

Shaw, Alice T., Tae Min Kim, Lucio Crinò, et al.. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 18(7). 874–886. 412 indexed citations breakdown →

Scagliotti, Giorgio V., Lucio Crinò, Geoffrey Liu, et al.. (2016). Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. Annals of Oncology. 27. vi579–vi579. 22 indexed citations

Mok, Tony, Giorgio V. Scagliotti, Lucio Crinò, et al.. (2016). 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ). Annals of Oncology. 27. ix142–ix143. 1 indexed citations

André, Fabrice, Thomas Bachelot, Mario Campone, et al.. (2013). Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clinical Cancer Research. 19(13). 3693–3702. 251 indexed citations

André, Fabrice, Patrick Neven, Antonino Musolino, et al.. (2013). Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study. Cancer Research. 73(24_Supplement). OT2–6. 2 indexed citations

10.

André, Fabrice, Patrick Neven, Antonino Musolino, et al.. (2013). Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study.. Journal of Clinical Oncology. 31(15_suppl). TPS651–TPS651. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact